June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Repeatability and Agreement of Optical Coherence Tomography Measurements Obtained with the Spectralis OCT2 and the New Spectralis OCT3
Author Affiliations & Notes
  • Mai Tsukikawa
    Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Alessandro A Jammal
    Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Henry Tseng
    Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Felipe Medeiros
    Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Sanjay Asrani
    Duke University Department of Ophthalmology, Durham, North Carolina, United States
  • Footnotes
    Commercial Relationships   Mai Tsukikawa None; Alessandro Jammal None; Henry Tseng Allergan, Code C (Consultant/Contractor); Felipe Medeiros Aerie Pharmaceuticals, Allergan, Annexon, Biogen, Carl Zeiss Meditec, Galimedix, IDx, Stealth Biotherapeutics, Reichert, Code C (Consultant/Contractor), Allergan, Carl Zeiss Meditec, Google Inc, Heidelberg Engineering, Novartis, Reichert, Code F (Financial Support), nGoggle Inc, Code P (Patent); Sanjay Asrani Heidelberg Engineering, Code R (Recipient)
  • Footnotes
    Support  NEI EY029885 and EY031898 (FAM)
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3327 – F0136. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mai Tsukikawa, Alessandro A Jammal, Henry Tseng, Felipe Medeiros, Sanjay Asrani; Repeatability and Agreement of Optical Coherence Tomography Measurements Obtained with the Spectralis OCT2 and the New Spectralis OCT3. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3327 – F0136.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The Spectralis OCT3 (Heidelberg Engineering, Heidelberg, Germany) is a new OCT device capable of faster image acquisition at 125,000 Hz, compared to 85,000 Hz of the current Spectralis OCT2. The purpose of this study was to evaluate the repeatability and agreement of optic disc and retinal nerve fiber layer (RNFL) parameters obtained by these 2 devices.

Methods : Normal and glaucoma eyes of adult subjects were recruited. OCT scans were obtained 3 times on the same day with the Spectralis OCT2 and Spectralis OCT3, by the same examiner. Sectoral and global RNFL thickness as well as global minimum rim width (MRW) and Bruch’s membrane opening area (BMOa) were measured. Repeatability was assessed by the coefficient of variation (COV) with bootstrapped 95% confidence interval (CI) for each parameter of each device. Bland-Altman plots were constructed to assess interdevice agreement.

Results : Included were 20 eyes from 20 subjects, with mean ± standard deviation (range) of 73.7 ± 18.0 µm (42.3 to 111.7 µm) for global RNFL, 219.0 ± 63.0 µm (86.3 to 358.3 µm) for global MRW, and 2.10 ± 0.5 mm2 (1.45 to 3.24 mm2) for BMOa measured by the Spectralis OCT2. Both Spectralis OCT2 and OCT3 showed similarly low COVs [95% CI] for global RNFL thickness (1.1% [0.4% to 1.9%] vs. 0.9% [0.6% to 1.2%], respectively), global MRW (1.0% [0.6% to 1.5] vs. 1.1% [0.8% to 1.4%], respectively), and BMOa (0.7% [0.5% to 0.9%] vs. 0.9% [0.6% to 1.2%], respectively). Bland-Altman 95% limits of agreement were -3.7 to 5.1 µm for RNFL, -5.0 to -3.9 µm for MRW, and -0.06 to 0.07 mm2 for BMOa, demonstrating good interdevice agreement for all parameters.

Conclusions : We found excellent intravisit repeatability of measurements for both devices. Bland-Altman limits of agreement were low, suggesting that measurements are potentially interchangeable between devices.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×